Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Zoledronic Acid in CML
NCT00210119Phase 2Terminated
- Sponsor
- Institut Bergonié
- Start
- Jul 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zoledronic acid in chronic myeloid leukemia (CML), sponsored by Institut Bergonié. Primary endpoint: Percentage of Participants With Molecular Response at 6 months. Started Jul 2006; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00210119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210119.